Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulators Reassure On AZ Vaccine Safety After Rare Side Effect Deemed Plausible

Vaccine Faces Global Confidence Test

Executive Summary

The EMA and MHRA issue parallel safety updates on the vaccine, with the UK offering an alternative of the Pfizer/BioNTech or Moderna vaccines to the under 30s.

You may also be interested in...



Has UK Got Vaccine Strategy Right Again With Choice For Under 30s?

The UK has announced a ‘course correction’ on its vaccination program, and looks to have maintained public confidence so far – unfortunately the same cannot be said for EU countries

Regulators Reassure On AZ Vaccine Safety After Rare Side Effect Deemed Plausible

The EMA and MHRA issue parallel safety updates on the vaccine, with the UK offering an alternative of the Pfizer/BioNTech or Moderna vaccines to the under 30s.

EMA Expected To Confirm AZ Vaccine Link To Rare Blood Clot

Growing evidence of an association between the vaccine and rare, sometimes fatal blood clots puts Europe’s vaccine program leaders in a difficult position.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel